• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白抑制剂作为抗糖尿病药物：综述

SGLT inhibitors as antidiabetic agents: a comprehensive review.

作者信息

Kshirsagar Rahul P, Kulkarni Abhishek A, Chouthe Rashmi S, Pathan Shahebaaz K, Une Hemant D, Reddy G Bhanuprakash, Diwan Prakash V, Ansari Siddique Akber, Sangshetti Jaiprakash N

机构信息

Yashodeep Institute of Pharmacy Aurangabad Maharashtra India - 431007.

Y. B. Chavan College of Pharmacy Aurangabad Maharashtra India - 431001

出版信息

RSC Adv. 2020 Jan 9;10(3):1733-1756. doi: 10.1039/c9ra08706k. eCollection 2020 Jan 7.

DOI:10.1039/c9ra08706k
PMID:35494673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9048284/
Abstract

Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time.

摘要

糖尿病是导致全球健康负担增加的最常见疾病之一。作为一种代谢紊乱疾病，糖尿病与多种病症和疾病相关，如肥胖症、高血压、心血管疾病和动脉粥样硬化。在本综述中，我们涵盖了过去十年间发表的关于钠/葡萄糖协同转运蛋白（SGLT）抑制剂的科学研究。我们致力于全面概述SGLT抑制剂，从而首次介绍了它们的化学分类。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/f1eb36cc2fba/c9ra08706k-p5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/4ab0e1405baa/c9ra08706k-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/eba103b4c7ee/c9ra08706k-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/0ff8f98a07a5/c9ra08706k-p1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/d170259ac266/c9ra08706k-p2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/d7cc59f4078d/c9ra08706k-p3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/de9d10ed4801/c9ra08706k-p4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/f1eb36cc2fba/c9ra08706k-p5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/4ab0e1405baa/c9ra08706k-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/eba103b4c7ee/c9ra08706k-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/0ff8f98a07a5/c9ra08706k-p1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/d170259ac266/c9ra08706k-p2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/d7cc59f4078d/c9ra08706k-p3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/de9d10ed4801/c9ra08706k-p4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c8a/9048284/f1eb36cc2fba/c9ra08706k-p5.jpg

相似文献

1
SGLT inhibitors as antidiabetic agents: a comprehensive review.钠-葡萄糖协同转运蛋白抑制剂作为抗糖尿病药物：综述
RSC Adv. 2020 Jan 9;10(3):1733-1756. doi: 10.1039/c9ra08706k. eCollection 2020 Jan 7.
2
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
3
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的应用与心原性猝死和全因死亡风险。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):18-25. doi: 10.1093/ehjcvp/pvac043.
4
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.钠-葡萄糖协同转运蛋白2抑制剂：除降糖作用外的潜在抗动脉粥样硬化效应
J Clin Med Res. 2016 Jan;8(1):10-4. doi: 10.14740/jocmr2385w. Epub 2015 Dec 3.
5
Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂在糖尿病心血管疾病中的新作用：聚焦免疫、炎症与代谢
Front Pharmacol. 2022 Feb 28;13:836849. doi: 10.3389/fphar.2022.836849. eCollection 2022.
6
Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.2012-2020 年日本用于治疗 2 型糖尿病的抗糖尿病药物处方趋势：时间序列分析。
Biol Pharm Bull. 2023;46(4):592-598. doi: 10.1248/bpb.b22-00710.
7
Cardiovascular effects of antidiabetic drugs.抗糖尿病药物的心血管效应。
Drugs Today (Barc). 2018 Sep;54(9):547-559. doi: 10.1358/dot.2018.54.9.2872500.
8
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
9
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.钠-葡萄糖共转运蛋白 2 抑制剂与二甲双胍作为二线治疗药物起始治疗 2 型糖尿病患者的心血管结局：一项队列研究。
Ann Intern Med. 2022 Jul;175(7):927-937. doi: 10.7326/M21-4012. Epub 2022 May 24.
10
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病合并非酒精性脂肪性肝炎患者中的疗效：证据回顾。
Front Endocrinol (Lausanne). 2021 Dec 7;12:768850. doi: 10.3389/fendo.2021.768850. eCollection 2021.

引用本文的文献

1
SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：从构效关系到药理反应
Int J Mol Sci. 2025 Jul 19;26(14):6937. doi: 10.3390/ijms26146937.
2
GC-MS profiling and computational analysis of Balanites aegyptiaca phytoconstituents for antidiabetic activity: insights from network pharmacology and molecular docking.埃及 balanites 植物成分的气相色谱-质谱联用分析及抗糖尿病活性的计算分析：来自网络药理学和分子对接的见解
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 6. doi: 10.1007/s00210-025-04187-8.
3
Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside.

本文引用的文献

1
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.钠-葡萄糖共转运蛋白抑制剂在 1 型糖尿病治疗中的作用及预防糖尿病酮症酸中毒的风险缓解策略：STOP DKA 方案。
Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. doi: 10.1111/dom.13811. Epub 2019 Jun 30.
2
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂依帕列净的体外药理特性
Biol Pharm Bull. 2019;42(3):507-511. doi: 10.1248/bpb.b18-00728.
3
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
心血管疾病和糖尿病中的外源性酮体：从实验台到病床边
J Clin Med. 2024 Dec 4;13(23):7391. doi: 10.3390/jcm13237391.
4
Biological Activities of Secondary Metabolites from the Edible-Medicinal Macrofungi.食药用大型真菌次生代谢产物的生物活性
J Fungi (Basel). 2024 Feb 11;10(2):144. doi: 10.3390/jof10020144.
5
Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections.发现口服生物可利用的 FmlH 凝集素拮抗剂作为尿路感染的治疗方法。
J Med Chem. 2024 Mar 14;67(5):3668-3678. doi: 10.1021/acs.jmedchem.3c02128. Epub 2024 Feb 3.
6
Multifaceted relationship between diabetes and kidney diseases: Beyond diabetes.糖尿病与肾脏疾病之间的多方面关系：超越糖尿病本身。
World J Diabetes. 2023 Oct 15;14(10):1450-1462. doi: 10.4239/wjd.v14.i10.1450.
7
Imidazo[1,2-c]quinazolines as a novel and potent scaffold of α-glucosidase inhibitors: design, synthesis, biological evaluations, and in silico studies.咪唑并[1,2-c]喹唑啉类作为新型强效α-葡萄糖苷酶抑制剂：设计、合成、生物评价和计算机模拟研究。
Sci Rep. 2023 Sep 21;13(1):15672. doi: 10.1038/s41598-023-42549-5.
8
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease.钠-葡萄糖协同转运蛋白2抑制剂在心血管疾病和慢性肾脏病中的多效性作用
J Clin Med. 2023 Apr 12;12(8):2824. doi: 10.3390/jcm12082824.
9
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为其抗动脉粥样硬化活性一部分的抗炎作用：来自基础科学和临床试验的数据。
Front Cardiovasc Med. 2022 Sep 6;9:1008922. doi: 10.3389/fcvm.2022.1008922. eCollection 2022.
10
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options.糖尿病中的冠状动脉微血管功能障碍：发病机制与潜在治疗选择
Biomedicines. 2022 Sep 14;10(9):2274. doi: 10.3390/biomedicines10092274.
钠-葡萄糖共转运蛋白 2 抑制剂治疗的 1 型糖尿病患者糖尿病酮症酸中毒风险管理的国际共识。
Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6.
4
11β Hydroxysteroid dehydrogenase - 1 activity in type 2 diabetes mellitus: a comparative study.2型糖尿病中11β-羟类固醇脱氢酶-1活性：一项对比研究。
BMC Endocr Disord. 2019 Jan 24;19(1):15. doi: 10.1186/s12902-019-0344-9.
5
SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant.SGLT2 抑制剂引起的血糖正常型糖尿病酮症酸中毒可能是由于易感个体中葡萄糖敏感性的突然、严重和短暂受损所致，这些个体存在尚未被认识到的β细胞 SGLT 变异。
Med Hypotheses. 2018 May;114:11-12. doi: 10.1016/j.mehy.2018.02.025. Epub 2018 Feb 24.
6
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.恩格列净与西格列汀起始联合治疗2型糖尿病患者：VERTIS SITA随机研究
Diabetes Ther. 2018 Feb;9(1):253-268. doi: 10.1007/s13300-017-0358-0. Epub 2018 Jan 8.
7
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.卡格列净对 2 型糖尿病老年患者心血管生物标志物的影响。
J Am Coll Cardiol. 2017 Aug 8;70(6):704-712. doi: 10.1016/j.jacc.2017.06.016. Epub 2017 Jun 12.
8
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：现状与未来展望
Eur J Pharm Sci. 2016 Oct 10;93:244-52. doi: 10.1016/j.ejps.2016.08.025. Epub 2016 Aug 12.
9
N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.作为钠依赖性葡萄糖协同转运蛋白2抑制剂的在葡萄糖C6位带有修饰的N-吲哚基糖苷。
Bioorg Med Chem. 2016 May 15;24(10):2242-50. doi: 10.1016/j.bmc.2016.03.058. Epub 2016 Mar 30.
10
Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design.舍格列净 -A的O-葡萄糖苷修饰：一种设计SGLT2抑制剂的新策略。
Bioorg Med Chem Lett. 2016 May 1;26(9):2170-3. doi: 10.1016/j.bmcl.2016.03.065. Epub 2016 Mar 16.